Pacira Biosciences, INC 8-K filings

Pacira BioSciences announced second quarter 2026 financial results, reporting total revenue of $192.4 million, a 6% year-over-year increase, alongside strategic advancements including the iovera divestiture and EXPAREL reimbursement expansion.

Pacira BioSciences announced an agreement to divest its iovera business to Zimmer Biomet for up to $140 million, including an upfront payment and potential future milestone payments.

Pacira BioSciences stockholders elected three directors and approved an amendment to the 2014 Employee Stock Purchase Plan.

Pacira BioSciences, Inc. announced record-high EXPAREL sales and strong full-year 2025 financial results, driven by its 5x30 strategy and strategic partnerships.

Pacira BioSciences, Inc. announced the appointment of Dr. Samit Hirawat, a veteran biopharmaceutical executive, to its Board of Directors, increasing the board size to 10 members.

Pacira BioSciences announced preliminary unaudited total revenue of $726.4 million for full-year 2025, driven by record-high EXPAREL sales.

Pacira BioSciences reported mixed third-quarter 2025 financial results, including a 6% revenue increase but a lowered full-year revenue guidance, alongside strategic advancements in its non-opioid pain therapy pipeline.

Pacira BioSciences reported a net loss in Q2 2025 despite revenue growth, driven by increased investments and strategic advancements in its non-opioid pain therapy portfolio.

Pacira BioSciences, Inc. announced a workforce reduction impacting 71 employees and the decommissioning of its 45-liter manufacturing suite in San Diego, driven by improved efficiencies from new large-scale production facilities.

Pacira BioSciences, Inc. has entered into a new $300 million senior secured revolving credit facility with Wells Fargo Bank, National Association, to refinance its existing credit agreement and provide ongoing working capital, maturing on July 3, 2030.

Pacira BioSciences, Inc. stockholders approved an amended stock incentive plan authorizing 2.5 million new shares but voted against the advisory proposal on executive officer compensation at their 2025 Annual Meeting.

Pacira BioSciences announced its first quarter 2025 financial results, reporting total revenues of $168.9 million and reaffirming its full-year 2025 financial guidance.

Pacira BioSciences' Board of Directors has approved a new share repurchase program authorizing the company to purchase up to $300 million of its common stock, replacing the previous program.

Pacira BioSciences reached a settlement with Fresenius Kabi, granting them licenses to sell volume-limited generic versions of EXPAREL starting in early 2030 and unlimited quantities starting in 2039.

Pacira BioSciences amended its bylaws to adopt a majority voting standard for uncontested director elections, effective immediately on March 12, 2025.

Pacira BioSciences announces record 2024 revenues of $701 million and outlines its 5x30 strategy to become a leader in musculoskeletal pain management.

Pacira BioSciences has appointed Laura Brege as the new Chair of the Board, following the resignations of Paul J. Hastings and Andreas Wicki, and has reduced the board size to nine members.

Pacira BioSciences appoints a new Chief Commercial Officer, shifts a current executive to a new role, and increases the number of shares available under its inducement plan.

Pacira BioSciences announced a new five-year plan targeting significant growth and a transition into an innovative biopharmaceutical company, alongside preliminary 2024 revenue of $701 million.

Pacira BioSciences announced its third quarter 2024 financial results, highlighting revenue growth but also a significant net loss due to a goodwill impairment.

Pacira BioSciences has appointed Shawn Cross as its new Chief Financial Officer, effective October 21, 2024.

Pacira BioSciences has appointed Lauren Riker as interim Chief Financial Officer, effective October 1, 2024, following the planned departure of Charles A. Reinhart, III.

Pacira BioSciences' board of directors rejected the resignation of director Laura Brege, who tendered her resignation after receiving a majority of withhold votes at the 2024 annual meeting.

Pacira BioSciences announced that a U.S. District Court ruled against the validity of their patent for EXPAREL, a key non-opioid pain management product.

Pacira BioSciences announced its second quarter 2024 financial results, highlighting revenue growth and strategic preparations for a key reimbursement change in 2025.

Pacira BioSciences reports the retirement of a board member, the approval of a consulting agreement amendment, and the results of its 2024 Annual Meeting of Stockholders.

Pacira BioSciences has announced the pricing of a $250 million convertible senior notes offering due in 2029, with an option for initial purchasers to buy an additional $37.5 million.

Pacira BioSciences plans to offer $250 million in convertible senior notes due 2029, using proceeds for debt repurchase, capped call transactions, and share buybacks.

Pacira BioSciences reported a solid start to 2024 with increased revenue and a new $150 million share repurchase program.

Pacira BioSciences announced record full-year revenues of $675 million for 2023, alongside the departure of its CFO, Charles A. Reinhart, III, effective September 30, 2024.